Skip to main content
Erschienen in: Clinical Rheumatology 6/2004

01.12.2004 | Original Article

Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies

verfasst von: Insoo Kang, Robyn Siperstein, Tim Quan, Mary Lou Breitenstein

Erschienen in: Clinical Rheumatology | Ausgabe 6/2004

Einloggen, um Zugang zu erhalten

Abstract

Monovariate and multivariate analyses including logistic regression were performed to determine associations among predicting variables [age, gender, immunofluorescence pattern, and anti-nuclear antibody (ANA) titer] and anti-extractable nuclear antigen (ENA) and -dsDNA antibodies (Abs) in 1089 patients with positive fluorescent ANA (FANA) test results. Samples with high titer ANAs had an increased frequency of anti-ENA and -dsDNA Abs. The receiver operating (ROC) curves of the ANA titer for anti-ENA Abs had a larger under the curve area compared to the ROC curve for anti-dsDNA Abs, indicating that ANA titer is better for predicting anti-ENA Abs than anti-dsDNA Abs. There was no relation noticed between immunofluorescence patterns and anti-ENA and -dsDNA Abs except an increased frequency of anti-dsDNA Abs found in samples with a homogeneous pattern. Probability calculations on the basis of the ANA pattern and the titer showed that samples with low titer ANAs (1:160 or less) had low probabilities for anti-ENA Abs (0.002–0.009) regardless of immunofluorescence patterns. However, samples with a homogeneous pattern at any titers including low titers had high probabilities for anti-dsDNA Abs. A decreased frequency of anti-dsDNA Abs as measured by Crithidia assay was noticed in samples from patients aged 50 or older. In contrast, no association was noticed between age and anti-ENA Abs. There was no female preponderance found in the presence of anti-ENA and -dsDNA Abs. In conclusion, our study shows that the ANA titer but not the immunofluorescence pattern is useful in predicting anti-ENA Abs. In contrast, both the ANA titer and the immunofluorescence pattern help in predicting anti-dsDNA Abs. Samples with low titer ANAs (1:160 or less) may not need a further test for anti-ENA Abs unless an ANA-associated disease is highly suspected. However, a test for anti-dsDNA Abs should be considered in samples with a homogeneous pattern at any titer including low titers.
Literatur
1.
Zurück zum Zitat Brown BW (1980) Prediction analyses for binary data. In: Miller RG, Efron B, Brown BW, Moses LE (eds) Biostatistics casebook. John Wiley and Sons, New York Brown BW (1980) Prediction analyses for binary data. In: Miller RG, Efron B, Brown BW, Moses LE (eds) Biostatistics casebook. John Wiley and Sons, New York
2.
Zurück zum Zitat Craig WY, Ledue TB, Johnson AM, Ritchie RF (1999) The distribution of antinuclear antibody titers in “normal” children and adults. J Rheumatol 26:914–919PubMed Craig WY, Ledue TB, Johnson AM, Ritchie RF (1999) The distribution of antinuclear antibody titers in “normal” children and adults. J Rheumatol 26:914–919PubMed
3.
Zurück zum Zitat de Vlam K, De Keyser F, Verbruggen G, et al. (1993) Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 11:393–397PubMed de Vlam K, De Keyser F, Verbruggen G, et al. (1993) Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin Exp Rheumatol 11:393–397PubMed
4.
Zurück zum Zitat Homburger HA (1995) Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 70:183–184PubMed Homburger HA (1995) Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 70:183–184PubMed
5.
Zurück zum Zitat Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124:71–81PubMed Kavanaugh A, Tomar R, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med 124:71–81PubMed
6.
Zurück zum Zitat Malleson PN, Sailer M, Mackinnon MJ (1997) Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 77:299–304PubMed Malleson PN, Sailer M, Mackinnon MJ (1997) Usefulness of antinuclear antibody testing to screen for rheumatic diseases. Arch Dis Child 77:299–304PubMed
7.
Zurück zum Zitat Peene I, Meheus L, Veys EM, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60:1131–1136CrossRefPubMed Peene I, Meheus L, Veys EM, De Keyser F (2001) Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Ann Rheum Dis 60:1131–1136CrossRefPubMed
8.
Zurück zum Zitat Peng SL, Hardin JA, Craft J (1997) Antinuclear antibodies. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) Text book of rheumatology. WB Saunders, Philadelphia, pp 250–266 Peng SL, Hardin JA, Craft J (1997) Antinuclear antibodies. In: Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (eds) Text book of rheumatology. WB Saunders, Philadelphia, pp 250–266
9.
Zurück zum Zitat Vaile JH, Dyke L, Kherani R, Johnston C, Higgins T, Russell AS (2000) Is high titre ANA specific for connective tissue disease? Clin Exp Rheumatol 18:433–438PubMed Vaile JH, Dyke L, Kherani R, Johnston C, Higgins T, Russell AS (2000) Is high titre ANA specific for connective tissue disease? Clin Exp Rheumatol 18:433–438PubMed
Metadaten
Titel
Utility of age, gender, ANA titer and pattern as predictors of anti-ENA and -dsDNA antibodies
verfasst von
Insoo Kang
Robyn Siperstein
Tim Quan
Mary Lou Breitenstein
Publikationsdatum
01.12.2004
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 6/2004
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-004-0937-0

Weitere Artikel der Ausgabe 6/2004

Clinical Rheumatology 6/2004 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.